Allarity announces presentation from Phase 2 trial with stenoparib monotherapy
Therapeutics announced the presentation of new clinical data from its ongoing Phase 2 trial with stenoparib monotherapy in ...
EurekAlert!13d
Chinese Medical Journal article reveals the anticancer potential of poly ADP-ribose polymerase inhibitors
Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...
Bianca Balti's Unyielding Fight
Two months after the last chemotherapy, Bianca Balti resumes her battle against cancer. Fresh from participating in the Milan ...
University of Birmingham12d
Understanding why PARP inhibitors may stop working for some cancer patients
New findings could help identify patients likely to become resistant to anti-cancer drugs and aid exploring different ways to ...
Yahoo Finance13d
Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA
LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with ...
CURE3d
Xtandi and Talzenna Therapy Shows Responses in Advanced Prostate Cancer
Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...
Allarity announes Phase 2 trial of stenoparib with temozolomide
Therapeutics announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylating ...
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
Business Wire13d
Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA
LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor in HRD (homologous recombination deficiency) cancers.